Unjoni Ewropea - Malti - EMA (European Medicines Agency)

laboratorios farmacéuticos rovi, s.a. - risperidone - skizofrenija - psikolettiċi - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaċċini - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 u 5. 1 in product information document). l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxo group ltd. - fluticasone furoate - rhinitis, allergic, perennial; rhinitis, allergic, seasonal - preparazzjonijiet imnieħer - adulti u adolexxenti (minn 12-il sena u ' l fuq) u tfal (6 - 11-il sena). alisade hija indikata għat-trattament tas-sintomi ta 'rinite allerġika.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - leukimija limfoblastika taċ-Ċelluli prekursuri-linfoma - aġenti antineoplastiċi - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gentium s.r.l. - defibrotide - mard epatiku-okklussiv tal-vini - aġenti antitrombotiċi - defitelio huwa indikat għall-kura ta ' severi epatiċi okklussivi veno marda (vod) magħrufa wkoll bħala sinusojdali eliminat syndrome (sos) f'terapija haematopoietic-ċelloli staminali trapjant (hsct). huwa indikat fl-adulti u fl-adoloxxenti, tfal u trabi ' l fuq minn 1 xahar ta'età.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amryt ag - betulae cortex - wounds and injuries; wound healing - preparazzjonijiet għat-trattament ta 'feriti u ulċeri - trattament ta 'feriti ta' ħxuna parzjali fl-adulti. ara t-taqsimiet 4. 4 u 5. 1 fl-informazzjoni dwar il-prodott fir-rigward tat-tip ta 'feriti studjati.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - afatinib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - giotrif bħala monoterapija hija indikata għat-trattament ofepidermal growth factor receptor (egfr) tki pazjenti adulti naΐve għal kura bil-lokalment avvanzat jew dak metastatiku li mhux ta 'ċelluli żgħar kanċer tal-pulmun (nsclc) ma' l-attivazzjoni tal-egfr-mutazzjoni tal - (s);lokalment avvanzat jew metastatiku nsclc tal-kanser skwamuż tar-istoloġija tal-progress fuq jew wara ibbażat fuq il-platinu ' kimoterapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

csl behring gmbh - immunoglobulina normali umana (scig) - sindromi ta 'defiċjenza immunoloġika - sera immuni u immunoglobulini, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

elanco gmbh - escherichia coli ħajjin mhux patoġeniċi o141: k94 (f18ac) u o8: k87 (f4ac) - immunologicals for suidae, live bacterial vaccines - majjali - għall-immunizzazzjoni attiva tal-majjali minn 18-il jum ta'l-età kontra l-enterotoxigenic f4-pożittivi u f18-pożittivi escherichia coli sabiex titnaqqas l-inċidenza ta moderat għal sever ta ' wara l-ftim e. coli diarrhea (pwd) fil-ħnieżer infettati u biex jitnaqqas it-tixrid tal-feċi ta 'e-enterotoxigenic f4 pożittiv u e pożittiv f18. coli minn ħnieżer infettati.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer limited - difloxacin - antibatteriċi għal użu sistemiku, antiinfectives għall-użu sistemiku - turkeys; dogs; cattle; chicken - tiġieġ:għat-trattament ta 'infezzjonijiet kroniċi respiratorji kkawżati minn strejns sensittivi ta' eschericia coli u mycoplasma gallisepticum. dundjani: għall-kura ta 'infezzjonijiet respiratorji kroniċi kkawżati minn razez sensittivi ta' escherichia coli u mycoplasma gallisepticum. ukoll għat-trattament ta 'infezzjonijiet ikkawżati minn pasteurella multocida. klieb: għat-trattament ta 'infezzjonijiet akuti mhux ikkomplikati ta' l-apparat urinarju kkawżati minn escherichia coli jew staphylococcus spp. u pyoderma superfiċjali kkawżata minn staphylococcus intermedius. baqar:għat-trattament tal-marda respiratorja bovina (shipping fever, pnewmonja fl-għoġliet) kkawżata minn doża waħda jew infezzjonijiet imħalta ma ' pasteurella haemolytica, pasteurella multocida, u / jew mycoplasma spp.